Cargando…

Compensatory intestinal immunoglobulin response after vancomycin treatment in humans

Intestinal immunoglobulins (Ig) are abundantly secreted antibodies that bind bacteria and bacterial components in the gut. This binding is considered to accelerate bacterial transit time and prevent the interaction of potentially immunogenic compounds with intestinal immune cells. Ig secretion is re...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheithauer, Torsten P. M., Bakker, Guido J., Winkelmeijer, Maaike, Davids, Mark, Nieuwdorp, Max, van Raalte, Daniël H., Herrema, Hilde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833805/
https://www.ncbi.nlm.nih.gov/pubmed/33475461
http://dx.doi.org/10.1080/19490976.2021.1875109
_version_ 1783642146238103552
author Scheithauer, Torsten P. M.
Bakker, Guido J.
Winkelmeijer, Maaike
Davids, Mark
Nieuwdorp, Max
van Raalte, Daniël H.
Herrema, Hilde
author_facet Scheithauer, Torsten P. M.
Bakker, Guido J.
Winkelmeijer, Maaike
Davids, Mark
Nieuwdorp, Max
van Raalte, Daniël H.
Herrema, Hilde
author_sort Scheithauer, Torsten P. M.
collection PubMed
description Intestinal immunoglobulins (Ig) are abundantly secreted antibodies that bind bacteria and bacterial components in the gut. This binding is considered to accelerate bacterial transit time and prevent the interaction of potentially immunogenic compounds with intestinal immune cells. Ig secretion is regulated by alterations in gut microbiome composition, an event rarely mapped in an intervention setting in humans. Here, we determined the intestinal and systemic Ig response to a major intervention in gut microbiome composition. Healthy humans and humans with metabolic syndrome received oral vancomycin 500 mg four times per day for 7 days. Coinciding with a vancomycin-induced increase in Gram-negative bacteria, fecal levels of the immunogenic bacterial components lipopolysaccharide (LPS) and flagellin drastically increased. Intestinal antibodies (IgA and IgM) significantly increased, whereas peripheral antibodies (IgG, IgA, and IgM) were mostly unaffected by vancomycin treatment. Bacterial cell sorting followed by 16S rRNA sequencing revealed that the majority of Gram-negative bacteria, including opportunistic pathogens, were IgA-coated after the intervention. We suggest that the intestinal Ig response after vancomycin treatment prevents the intrusion of pathogens and bacterial components into systemic sites.
format Online
Article
Text
id pubmed-7833805
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78338052021-02-02 Compensatory intestinal immunoglobulin response after vancomycin treatment in humans Scheithauer, Torsten P. M. Bakker, Guido J. Winkelmeijer, Maaike Davids, Mark Nieuwdorp, Max van Raalte, Daniël H. Herrema, Hilde Gut Microbes Research Paper Intestinal immunoglobulins (Ig) are abundantly secreted antibodies that bind bacteria and bacterial components in the gut. This binding is considered to accelerate bacterial transit time and prevent the interaction of potentially immunogenic compounds with intestinal immune cells. Ig secretion is regulated by alterations in gut microbiome composition, an event rarely mapped in an intervention setting in humans. Here, we determined the intestinal and systemic Ig response to a major intervention in gut microbiome composition. Healthy humans and humans with metabolic syndrome received oral vancomycin 500 mg four times per day for 7 days. Coinciding with a vancomycin-induced increase in Gram-negative bacteria, fecal levels of the immunogenic bacterial components lipopolysaccharide (LPS) and flagellin drastically increased. Intestinal antibodies (IgA and IgM) significantly increased, whereas peripheral antibodies (IgG, IgA, and IgM) were mostly unaffected by vancomycin treatment. Bacterial cell sorting followed by 16S rRNA sequencing revealed that the majority of Gram-negative bacteria, including opportunistic pathogens, were IgA-coated after the intervention. We suggest that the intestinal Ig response after vancomycin treatment prevents the intrusion of pathogens and bacterial components into systemic sites. Taylor & Francis 2021-01-21 /pmc/articles/PMC7833805/ /pubmed/33475461 http://dx.doi.org/10.1080/19490976.2021.1875109 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Scheithauer, Torsten P. M.
Bakker, Guido J.
Winkelmeijer, Maaike
Davids, Mark
Nieuwdorp, Max
van Raalte, Daniël H.
Herrema, Hilde
Compensatory intestinal immunoglobulin response after vancomycin treatment in humans
title Compensatory intestinal immunoglobulin response after vancomycin treatment in humans
title_full Compensatory intestinal immunoglobulin response after vancomycin treatment in humans
title_fullStr Compensatory intestinal immunoglobulin response after vancomycin treatment in humans
title_full_unstemmed Compensatory intestinal immunoglobulin response after vancomycin treatment in humans
title_short Compensatory intestinal immunoglobulin response after vancomycin treatment in humans
title_sort compensatory intestinal immunoglobulin response after vancomycin treatment in humans
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833805/
https://www.ncbi.nlm.nih.gov/pubmed/33475461
http://dx.doi.org/10.1080/19490976.2021.1875109
work_keys_str_mv AT scheithauertorstenpm compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans
AT bakkerguidoj compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans
AT winkelmeijermaaike compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans
AT davidsmark compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans
AT nieuwdorpmax compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans
AT vanraaltedanielh compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans
AT herremahilde compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans